- Home
- ANVS vs IGMS Comparison
ANVS vs IGMS Comparison
Compare ANVS & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANVS
- IGMS
- Stock Information
- Founded
- ANVS 2008
- IGMS 1993
- Country
- ANVS United States
- IGMS United States
- Employees
- ANVS N/A
- IGMS N/A
- Industry
- ANVS Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- ANVS Health Care
- IGMS Health Care
- Exchange
- ANVS Nasdaq
- IGMS Nasdaq
- Market Cap
- ANVS 92.6M
- IGMS 82.1M
- IPO Year
- ANVS 2020
- IGMS 2019
- Fundamental
- Price
- ANVS $2.13
- IGMS $1.38
- Analyst Decision
- ANVS Strong Buy
- IGMS Hold
- Analyst Count
- ANVS 6
- IGMS 8
- Target Price
- ANVS $31.40
- IGMS $6.14
- AVG Volume (30 Days)
- ANVS 684.1K
- IGMS 368.0K
- Earning Date
- ANVS 03-31-2025
- IGMS 03-06-2025
- Dividend Yield
- ANVS N/A
- IGMS N/A
- EPS Growth
- ANVS N/A
- IGMS N/A
- EPS
- ANVS N/A
- IGMS N/A
- Revenue
- ANVS N/A
- IGMS $2,918,000.00
- Revenue This Year
- ANVS N/A
- IGMS $26.85
- Revenue Next Year
- ANVS N/A
- IGMS $125.17
- P/E Ratio
- ANVS N/A
- IGMS N/A
- Revenue Growth
- ANVS N/A
- IGMS 57.64
- 52 Week Low
- ANVS $2.08
- IGMS $1.26
- 52 Week High
- ANVS $20.00
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- ANVS 18.43
- IGMS 26.21
- Support Level
- ANVS $2.08
- IGMS $1.26
- Resistance Level
- ANVS $2.79
- IGMS $1.54
- Average True Range (ATR)
- ANVS 0.32
- IGMS 0.13
- MACD
- ANVS -0.06
- IGMS 0.22
- Stochastic Oscillator
- ANVS 2.08
- IGMS 29.27
About ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.